Collaboration will provide access to data around real-time outcomes including clinical trial matches and cost analysis to the network of...
Randomized (TASTE) Trial In Early Stage Non-Small Cell Lung Cancer Trial, Demonstrates That GPS Proteomics Analysis Could Predict Tumor Response...
Company continues strong momentum for its comprehensive molecular test for cancer care and driving the era of clinical proteomics by...
Oncologists in United Arab Emirates, Saudi Arabia, Kuwait, Oman, Bahrain, Qatar, and Lebanon will be empowered to make more informed clinical decisions to personalize treatment and care for their...
New Jersey’s largest health insurance plan to reimburse for comprehensive molecular test in investigational cancer studies across four mid-Atlantic health...
Community oncologists will now have access to comprehensive tests to help them make better informed clinical decisions aimed at personalizing...
GPS Cancer will allow physicians to identify personalized treatments for children with rare, refractory or recurrent cancers for whom conventional...
One of the nation’s leading pediatric hospitals to adopt GPS Cancer™, a comprehensive molecular testing platform for personalized cancer therapy,...
Key thought leaders to collaborate on development of GPS Cancer™ guided combination immunotherapy clinical trial protocols for patients with deadliest form of...
1,000 individuals will undergo whole genome sequencing and whole transcriptome sequencing using a novel genomic testing platform provided by NantHealth CULVER...
With the Breast Cancer Working Group already announced, the pace of collaboration is accelerating to launch QUILT trials across all...
GPS Cancer™ combines the power of quantitative proteomics with genomics and transcriptomics to understand the “molecular fingerprint” of a cancer patient’s...